Amylyx Pharmaceuticals, Inc. (AMLX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Amylyx Pharmaceuticals, Inc. (AMLX)
Company Performance

Current Price

as of Oct 23, 2024

$4.96

P/E Ratio

N/A

Market Cap

$337.69M

Description

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAMLX
  • Price$4.96+9.49%

Trading Information

  • Market Cap$337.69M
  • Float60.53%
  • Average Daily Volume (1m)1,537,616
  • Average Daily Volume (3m)1,263,004
  • EPS-$2.44

Company

  • Revenue$298.76M
  • Rev Growth (1yr)-101.04%
  • Net Income-$72.70M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$53.23M
  • EV-$177.42M
  • EV/Revenue-0.59
  • P/EN/A
  • P/S1.13
  • P/B1.29
Documents
SEC Filings
8-K (2024-10-17)
8-K (2024-08-08)
8-K (2024-07-10)
8-K (2024-06-21)
8-K (2024-06-06)
8-K (2024-05-09)
8-K (2024-04-10)
8-K (2024-04-04)
8-K (2024-03-14)
8-K (2024-03-08)
8-K (2024-02-22)
8-K (2023-12-07)
8-K (2023-11-09)
8-K (2023-10-13)
8-K (2023-08-10)
8-K (2023-07-26)
8-K (2023-06-23)
8-K (2023-06-09)
8-K (2023-05-11)
8-K (2023-03-21)
8-K (2023-03-13)
8-K (2023-02-14)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-02-22)
10-K (2023-03-13)
Wikipedia
Amylyx_Pharmaceuticals
Factset Street Account
The European Medicines Agency has confirmed its recommendation to refuse Amylyx a marketing authorisation for the Albrioza ($17.61, 0.00) (2023-10-13T12:03:56Z)
StreetAccount Earnings Call Q&A Summary: Amylyx Pharmaceuticals Q3 ($12.81, -5.19) (2023-11-09T17:43:55Z)
France grants compassionate access to Amylyx Pharmaceuticals' AMX0035 for eligible people living with amyotrophic lateral sclerosis ($17.77, 0.00) (2023-10-05T21:31:31Z)
EU CHMP publishes summary of opinions for October meeting (2023-10-13T12:00:38Z)
Amylyx Pharmaceuticals reports Q3 EPS $0.30 vs FactSet $0.44 [4 est, $0.39-0.47] ($18.00, 0.00) (2023-11-09T12:07:31Z)
Amylyx Pharmaceuticals appoints Camille Bedrosian as Chief Medical Officer ($12.93, 0.00) (2023-11-28T12:05:20Z)
Amylyx Pharmaceuticals again receives negative CHMP opinion on its MAA for AMX0035 in ALS following re-examination process ($17.61, 0.00) (2023-10-13T11:47:50Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q1
Earnings Report (2023-11-11)
Earnings Report (2023-08-10)
Factset
Factset Business Description